Liquidia is a biopharmaceutical company focused on the development, manufacturing and commercialization of products that address unmet patient needs, with focus directed towards the treatment of pulmonary hypertension (PH). Co. conducts research, development and manufacturing of products by applying its proprietary PRINT® technology, a particle engineering platform, to enable production of drug particles. Co. has developed two product candidates for which it holds worldwide commercial rights: LIQ861 to treat pulmonary arterial hypertension, and LIQ865 to treat post-operative pain and are evaluating formulations of additional molecules to support new product candidates. The LQDA stock yearly return is shown above.
The yearly return on the LQDA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LQDA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|